The Pulse
Lilly’s oral GLP-1 is now shipping in the US
The FDA approved Foundayo (orforglipron) on April 1, and it started shipping via LillyDirect on April 6. First oral GLP-1 for weight loss with no food or water restrictions.
For telehealth operators built entirely around injectables, this creates an urgent product catalog question: do you add the oral option, or watch patients leave for brands that already have?
The brands that build onboarding and retention flows for oral GLP-1 patients first will own the next 12 months of this category.
FDA warned 30 telehealth firms over compounded GLP-1 marketing
The FDA issued warning letters to 30 telehealth companies for misleading claims about compounded semaglutide and tirzepatide products. Including branding compounded drugs with the company’s name as if they were proprietary.
This is the clearest signal yet that the compounding window is closing.
If your revenue depends on compounded GLP-1s, your retention system is the only thing that keeps patients with you when the product supply shifts underneath you.
Hims & Hers confirms customer data breach
Hackers accessed Hims’ third-party customer support system between February 4-7. Stolen: support tickets containing customer names and email addresses.
Medical records were not compromised.
But for an industry where patient trust is the entire product, even a support ticket breach sends a signal. Smaller telehealth brands should audit their own third-party integrations now, not after a headline forces them to.
Medicare now covers GLP-1s for obesity
Starting April 2026, Medicare covers GLP-1 medications for members with obesity and related conditions.
Millions of new patients enter the market through insurance channels, not through your intake funnel.
The operators who build Medicare-specific onboarding flows and adjust their messaging for an older, insurance-covered demographic will capture this wave. Everyone else will watch it pass.
The Deep Dive: Three Shifts That Just Broke Your GLP-1 Retention Playbook
Last week, three things happened simultaneously that change the economics of patient retention for every weight loss telehealth brand.
Most operators are treating these as separate news items. They’re not.
Together, they reshape who your patients are, how they find you, and how long they stay.
1. Oral GLP-1 removes the injection barrier, but creates a new retention problem.
Lilly’s Foundayo means patients who hesitated because of needles now have a daily pill option. That expands your addressable market.
But it also changes patient behavior in ways most retention flows aren’t built for:
Injectable patients have a built-in ritual. Weekly injection. Physical reminder of commitment.
Pill patients don’t. A daily pill blends into the background. Easier to start, easier to forget.
The side effect profile is different. Oral GLP-1 patients report more GI issues in the first two weeks.
If your onboarding flow was designed around injection-day check-ins and syringe education, it needs a parallel track for oral patients.
Your day 3-14 emails need to address the GI side effects specifically, or you’ll lose them before the medication has a chance to work.
2. Medicare coverage floods the market with a different patient profile.
Medicare GLP-1 coverage means millions of patients over 65 enter through insurance, not cash-pay.
These patients have different expectations:
They’re used to provider relationships, not DTC funnels
They expect clinical communication, not marketing emails
They churn for different reasons: formulary changes, prior authorization friction, provider switching
Your welcome flow, your onboarding copy, and your cross-sell timing all need to account for a patient who didn’t find you through an Instagram ad.
The brands that build a separate lifecycle track for insurance-covered patients will retain them. The ones that run everyone through the same funnel will wonder why their month-2 churn just spiked with a demographic they never expected.
3. FDA enforcement is shrinking the compounded supply, fast.
Thirty warning letters in one round. State legislatures tightening compounding rules. Novo Nordisk’s deal with Hims signals that branded manufacturers are reclaiming distribution.
For any telehealth brand whose entire model depends on compounded semaglutide or tirzepatide, the transition timeline just accelerated.
The retention implication is direct: when your product changes (compounded to branded, or injection to oral), patients experience disruption.
Price changes
Packaging changes
Sometimes dosing changes
Every one of those is a churn trigger.
The brands that communicate proactively through the transition will keep patients. The ones that surprise patients with a different product in the mail will not.
The takeaway:
If your retention system was built for a single product type, a single patient demographic, and a stable supply chain, all three of those assumptions broke this week.
The fix isn’t complicated, but it is urgent:
Segment by product type
Build parallel onboarding tracks
Communicate every change before the patient discovers it themselves
Quick Takes
The trust cost of a data breach is asymmetric
Hims’ breach exposed support tickets, not medical records. Most patients won’t even notice.
But the ones who do will Google it, find the headline, and question every email you send for the next six months.
In telehealth, trust compounds slowly and breaks fast.
If you’re relying on third-party tools for any patient-facing communication, audit your vendor security now. The breach that damages your brand won’t come from your own systems. It’ll come from a tool you forgot you connected.
Your CRM age is not your CRM maturity
Talked to a telehealth founder last month doing seven figures in monthly revenue. They set up Customer.io in November.
Four months of having a CRM, zero flows running, no segmentation beyond “customer” and “non-customer.”
Having the tool is not the same as having the infrastructure. A CRM without flows, segments, and content strategy is just a database with a monthly invoice.
One Thing to Try This Week
Pull your current product catalog and check how many of your automated flows reference a specific product format (injectable, pill, gel, spray…).
If the answer is “all of them reference one format,” you have a single point of failure.
This week, duplicate your highest-performing onboarding flow and rewrite the first three emails for a different product type. Change the side effect guidance, the expectation-setting timeline, and the check-in triggers.
You don’t need to launch it today. But having a second track ready means you can adapt in days instead of weeks when the product mix shifts.
And it will shift.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.